Originalkatalog | Verfügbarkeit prüfen

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nat...

Rolof G.P. Gijtenbeek, Ronald A.M. Damhuis, Anthonie J. van der Wekken, Lizza E.L. Hendriks, Harry J.M. Groen, Wouter H. van Geffen
Veröffentlicht in: The Lancet Regional Health. Europe, Vol 27, Iss , Pp 100592- (2023);
2023

Originalkatalog | Verfügbarkeit prüfen

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands

Anneloes L. Noordhof, MD, Esther M. Swart, MSc, Ronald A.M. Damhuis, PhD, Lizza E.L. Hendriks, MD, PhD, Peter W.A. Kunst, MD, PhD, Mieke J. Aarts, PhD, Wouter H. van Geffen, MD, PhD
Veröffentlicht in: JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100543- (2023);
2023

Originalkatalog | Verfügbarkeit prüfen

Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) pa...

M.C. Garassino, Boris Duchemann, David Planchard, J.J. Medhi, Lydie Cassard, Laura Mezquita, M. Naigeon, L. Boselli, Roberto Ferrara, Jonathan Grivel, Aude Desnoyer, Nathalie Chaput, Sabina Sangaletti, Edouard Auclin, Lizza E.L. Hendriks, Benjamin Besse, Caroline Caramella, J. Remon-Masip
2019